Exasol (EXL) Q4 2024 TU earnings summary

Executive summary

• Achieved profitability in 2024 with €2.0m EBITDA, positive net income, and positive cash flow for the first time since IPO, marking a turnaround from prior years of losses.

• Revenue grew 13% year-over-year to €39.6m; ARR increased 4% to €42.3m.

• Strategic focus on on-premise and hybrid solutions for regulated verticals (finance, healthcare) drove 19–20% ARR growth in these segments.

• Growth in focus verticals offset by higher churn and ARR decline in non-focus verticals, especially retail and business services.

• Signed 10 new customers worth €700k and secured a major 5-year upsell deal exceeding €10m.

Financial highlights

• EBITDA reached €2.0m in 2024, up from -€5.7m in 2023; net income positive at €0.3m in Q4 2024.

• Liquidity improved to €15.0m at year-end 2024, exceeding expectations.

• Operating expenses reduced to €38m from €41m in 2023, reflecting efficiency measures.

• Gross profit for 2024 was €39.6m, with recurring revenue at €38.9m.

• Personnel and marketing expenses declined, supporting margin improvement.

Outlook and guidance

• 2025 guidance targets mid single-digit growth in both ARR and revenue.

• EBITDA expected to rise to €3.0–4.0m, at least 50% above 2024.

• Anticipates continued or accelerated double-digit ARR growth in focus verticals after 2025.

• Cost base to remain flat in 2025, with reinvestment in R&D and product, especially AI.

• Liquid funds and positive net income expected to increase again in 2025.